MARKET

PRME

PRME

Prime Medicine
NASDAQ
3.385
-0.115
-3.29%
Opening 13:30 12/29 EST
OPEN
3.450
PREV CLOSE
3.500
HIGH
3.510
LOW
3.340
VOLUME
1.65M
TURNOVER
--
52 WEEK HIGH
6.94
52 WEEK LOW
1.110
MARKET CAP
611.03M
P/E (TTM)
-2.3481
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PRME last week (1222-1226)?
Weekly Report · 8h ago
Ametek, MindMed, Atai, Prime and KB Home Trending
TipRanks · 2d ago
Prime Medicine Price Target Announced at $6.00/Share by LifeSci Capital
Dow Jones · 6d ago
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6
Benzinga · 6d ago
Prime Medicine initiated with an Outperform at LifeSci Capital
TipRanks · 6d ago
Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease
TipRanks · 6d ago
Weekly Report: what happened at PRME last week (1215-1219)?
Weekly Report · 12/22 09:37
Weekly Report: what happened at PRME last week (1208-1212)?
Weekly Report · 12/15 09:40
More
About PRME
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Webull offers Prime Medicine Inc stock information, including NASDAQ: PRME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRME stock methods without spending real money on the virtual paper trading platform.